Chief Medical Officer MB BS BSc(Med)(Hons) FACEM MBA
Glenn is a founder and the Chief Medical Officer for Genepath. He has cross disciplinary expertise as paediatric emergency specialist, a molecular geneticist, and entrepreneur. With over 15 years experience in the public health sector, his strength is driving health system-wide uptake of innovative medical technology.
Dr Bennett Shum
Chief Scientific Officer BMedSci(Hons), PhD, MBA
Ben is a founder and Chief Scientific Officer of Genepath. He trained at Garvan Institute and Harvard Medical School and is Adjunct Senior Lecturer at University of New South Wales. Ben helped implement genomic testing technology to hospitals throughout Australia and is passionate about developing genomic solutions that can save lives across the globe.
Paulette has over 19 years of industry experience developing genomic solutions. She has been a leader in implementing first in Australia clinical genomic testing technology for a major Australian IVF provider, which was subsequently adopted internationally. Paulette has a passion for science and scientific discoveries to improve outcomes and the lives of others.
Prof Deon Venter
Deon is a histopathologist with a PhD in Molecular Genetics. He is a Professor of Pathology, School of Medicine, The University of Wollongong, NSW and a pathology advisor at Genepath. His interest is in utilising the interface between biological science and pathology to improve medical practice. Disciplines utilised during his career have included: Histopathology, perinatal pathology, genetics, genomics, proteomics, basic biological research, bioinformatics, computational biology, translational research, management, biotechnology and business management.
European Medical Advisor MD
Emre has over 15 years of experience in medical research and industry experience in major pharmaceutical and biotech companies. Early in his career he lead basic research at Harvard Medical School into the development of a novel therapeutic product for HIV infection. Recently, Emre launched a new oncology treatment for a European biopharmaceutical company. He is passionate about innovative medical technology especially digital health and increasing access to healthcare.
Chief Marketing Officer
Cheyne is the Chief Marketing Officer and brings over 12 years marketing experience. Previously he has worked for pharmaceutical (prescription & OTC) medicines and healthcare services.
B.Bus, CPA, CFA Charterholder
Nathan is a finance, investment and M&A professional with over 20 years of finance and direct investment (private equity and infrastructure) experience. Nathan has spent most of his career working in the private equity industry, commencing his private equity career in 2002. Since 2012, Nathan has worked at a number of corporates including at Boral Limited and at Right2Drive. Nathan was involved in the start-up of Right2Drive (commenced operations in 2012) that was subsequently sold to Eclipx Limited in May 2016 for A$67 million. Nathan is currently the CFO of a leading Australian land lease communities business, providing secure, affordable, quality lifestyle communities for Australians.